Edwards Lifesciences exec sells 544 EW shares

Edwards Lifesciences Corp (EW) executive Andrew M. Dahl, SVP, Corporate Controller, reported a sale of 544 shares of Common Stock on 2026-08-31 at $91.055 per share in an open-market or private transaction.

Rhea-AI Filing Summary

Edwards Lifesciences Corp (EW) executive Andrew M. Dahl, SVP, Corporate Controller, reported a sale of 544 shares of Common Stock on 2026-08-31 at $91.055 per share in an open-market or private transaction. After this sale, he directly holds 14,868.41 shares of Edwards Lifesciences common stock. The filing states it reflects changes in beneficial ownership and notes quarterly acquisition of shares under the company’s Employee Stock Purchase Plan. The Rule 10b5-1 trading-plan box is not checked.

Insider Trade Summary

Net Seller: 544 shares

Net Sell 1 txn

Insider Dahl Andrew M.

Role SVP, Corporate Controller

Sold 544 shs ($50K)

Type	Security	Shares	Price	Value
Sale	Common Stock	544	$91.055	$50K

Holdings After Transaction: Common Stock — 14,868.41 shares (Direct)

Key Figures

Shares sold: 544 shares of Common Stock Sale price per share: $91.055 per share Shares owned after transaction: 14,868.41 shares

3 metrics

Shares sold 544 shares of Common Stock Sale reported for 2026-08-31

Sale price per share $91.055 per share Price for the 544-share sale on 2026-08-31

Shares owned after transaction 14,868.41 shares Directly owned by Andrew M. Dahl following the sale

Key Terms

beneficial ownership, Employee Stock Purchase Plan, Common Stock, Rule 10b5-1

4 terms

beneficial ownership financial

"This Form 4 reflects changes in beneficial ownership only"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

Employee Stock Purchase Plan financial

"includes quarterly acquisition of shares under the Issuer's Employee Stock Purchase Plan"

An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.

Common Stock financial

"security_title: "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Rule 10b5-1 regulatory

"The Rule 10b5-1 trading-plan box is not checked"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

FAQ

What insider transaction did EW report for Andrew M. Dahl?

Edwards Lifesciences (EW) reported that Andrew M. Dahl sold 544 shares of Common Stock on 2026-08-31 in an open-market or private transaction at a price of $91.055 per share.

How many EW shares does Andrew M. Dahl own after this Form 4 transaction?

After the reported sale, Andrew M. Dahl directly owns 14,868.41 shares of Edwards Lifesciences (EW) Common Stock, according to the Form 4.

Was the 2026-08-31 EW stock sale by Andrew M. Dahl under a Rule 10b5-1 plan?

No. The Rule 10b5-1 checkbox is not marked, indicating the 544-share sale by Andrew M. Dahl on 2026-08-31 was not reported as executed under a Rule 10b5-1 trading plan.

What price did Andrew M. Dahl receive per EW share in the reported sale?

Andrew M. Dahl’s reported sale of Edwards Lifesciences (EW) Common Stock on 2026-08-31 was executed at a price of $91.055 per share.

Does this EW Form 4 mention the Employee Stock Purchase Plan?

Yes. The Form 4 remarks state that it includes quarterly acquisition of shares under Edwards Lifesciences’ Employee Stock Purchase Plan, in addition to the reported sale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/31/2026 - 05:48 PM Accepted by SEC EDGAR 08/31/2026 - 05:47 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dahl Andrew M.

(Last) (First) (Middle)

ONE EDWARDS WAY

(Street)

IRVINE CALIFORNIA 92614

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Edwards Lifesciences Corp [ EW ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Corporate Controller

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/31/2026		S		544	D	$91.055	14,868.41	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. This Form 4 includes quarterly acquisition of shares under the Issuer's Employee Stock Purchase Plan.

	Linda J. Park, Attorney-in-Fact	08/31/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)